Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives

Abstract

Colorectal cancer (CRC) represents the second most common cancer in Europe with marked differences in prognosis and response to treatments. In the past years research showed emerging interest in genomic and immunologic fields. The clinical heterogeneity, that occurs during the pathogenesis of CRC, is driven by chromosomal alterations and defective function of DNA mismatch repair genes. CRC is classified in four consensus molecular subtypes (CMS) with different immunogenic characteristics and prognosis. CMS1 microsatellite instable (MSI)-like and CMS4, both characterized by high levels of immune infiltration, are recognized as the most immunogenic subtypes, even though functional characteristic leading to different prognosis are reported. In particular, MSI tumors have been identified as the best candidates for immunotherapy treatment and a number of studies have evaluated the efficacy of anti-programmed cell death ligand-1 (PDL-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) in this setting. However, literature data show that the majority of patients with CRC have microsatellite stable (MSS) tumors and this status seems related to lower response to PDL-1/programmed cell death-1 or CTLA4 blockade. The aim of this paper is to investigate the role of immunotherapy in MSI and MSS CRC.

Keywords

Colorectal cancer / immunotherapy / microsatellite instable / microsatellite stable mismatch repair / prognosis

References

[1] Van Cutsem E,Adam R,Van Krieken JH.ESMO consensus guidelines for the management of patients with metastatic colorectal cancer..Ann Oncol2016;27:1386-422

[2] Siegel RL,Jemal A.Cancer statistics, 2016..CA Cancer J Clin2016;66:7-30

[3] Grady WM.Genomic and epigenetic instability in colorectal cancer pathogenesis..Gastroenterology2008;135:1079-99 PMCID:PMC2866182

[4] de la Chapelle A.Clinical relevance of microsatellite instability in colorectal cancer..J Clin Oncol2010;28:3380-7 PMCID:PMC2903331

[5] de Weger VA,Voorham QJ,Bril H.Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer..Clin Cancer Res2012;18:882-9

[6] Boland CR,Hamilton SR,Eshleman JR.A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer..Cancer Res1998;58:5248-57

[7] Hermsen M,Baak J,Rapallo A.Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability..Gastroenterology2002;123:1109-19

[8] Meijer GA,Baak JP,Meuwissen SG.Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation..J Clin Pathol1998;51:901-9 PMCID:PMC501025

[9] Merok MA,Røyrvik EC,Hektoen M.Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series..Ann Oncol2013;24:1274-82 PMCID:PMC3629894

[10] Samowitz WS,Ma KN,Coleman LW.Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level..Cancer Epidemiol Biomarkers Prev2001;10:917-23

[11] Gelsomino F,Spallanzani A,Cascinu S.The evolving role of microsatellite instability in colorectal cancer: a review..Cancer Treat Rev2016;51:19-26

[12] Segal NH,Peggs KS,Kinzler KW.Epitope landscape in breast and colorectal cancer..Cancer Res2008;68:889-92

[13] Roelands J,Vermeulen L,Decock J.Immunogenomic classification of colorectal cancer and therapeutic implications..Int J Mol Sci2017; PMCID:PMC5666908

[14] Voena C.Advances in cancer immunology and cancer immunotherapy..Discov Med2016;21:125-133

[15] Schiavoni G,Mattei F.The tumor microenvironment: apitch for multiple players..Front Oncol2013;3:90 PMCID:PMC3628362

[16] Herrera M,Domínguez G,García V.Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients..Cancer Sci2013;104:437-44

[17] Basile D,Bonotto M,Casagrande M.Immunotherapy for colorectal cancer: where are we heading?.Expert Opin Biol Ther2017;17:709-21

[18] Pagès F,Mlecnik B,Tosolini M.In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer..J Clin Oncol2009;27:5944-51

[19] Mlecnik B,Kirilovsky A,Bindea G.Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction..J Clin Oncol2011;29:610-8

[20] Zaretsky JM,Shin DS,Hugo W.Mutations associated with acquired resistance to pd-1 blockade in melanoma..N Engl J Med2016;375:819-29 PMCID:PMC5007206

[21] Shin DS,Escuin-Ordinas H,Hu-Lieskovan S.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations..Cancer Discov2017;7:188-201 PMCID:PMC5296316

[22] Le DT,Smith KN,Bartlett BR.Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade..Science2017;357:409-13 PMCID:PMC5576142

[23] Khong HT.Natural selection of tumor variants in the generation of “tumor escape” phenotypes..Nat Immunol2002;3:999-1005 PMCID:PMC1508168

[24] Brzostek J,Rybakin V.Cell type-specific regulation of immunological synapse dynamics by B7 ligand recognition..Front Immunol2016;7:24 PMCID:PMC4740375

[25] Galon J,Marincola FM,Trinchieri G.The immune score as a new possible approach for the classification of cancer..J Transl Med2012;10:1 PMCID:PMC3269368

[26] Galon J,Marincola FM,Thurin M.Cancer classification using the immunoscore: a worldwide task force..J Transl Med2012;10:205 PMCID:PMC3554496

[27] Guinney J,Wang X,Schlicker A.The consensus molecular subtypes of colorectal cancer..Nat Med2015;21:1350-6 PMCID:PMC4636487

[28] Becht E,Giraldo NA,Buttard B.Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy..Clin Cancer Res2016;22:4057-66

[29] Isella C,Bellomo SE,Zanella E.Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer..Nat Commun2017;8:15107 PMCID:PMC5499209

[30] Llosa NJ,Tam A,Hechenbleikner EM.The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints..Cancer Discov2015;5:43-51 PMCID:PMC4293246

[31] Verhagen J,Wraith DC.The role of CTLA-4 in immune regulation..Immunol Lett2008;115:73-4 PMCID:PMC2629540

[32] Buchbinder EI.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition..Am J ClinOncol2016;39:98-106 PMCID:PMC4892769

[33] Nishimura H,Tanaka Y,Hara M.Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice..Science2001;291:319-22

[34] Chamoto K,Honjo T.Role of PD-1 in immunity and diseases..Curr Top Microbiol Immunol2017;410:75-97

[35] Le DT,Wang H,Kemberling H.PD-1 blockade in tumors with mismatch-repair deficiency..N Engl J Med2015;372:2509-20 PMCID:PMC4481136

[36] Andre T,Wong M,Gelsomino F.Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): first report of the full cohort from CheckMate-142..J Clin Oncol2018;

[37] Overman MJ,Wong KYM,Gelsomino F.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer..J Clin Oncol2018;36:773-9

[38] Larkin J,Gonzalez R,Cowey CL.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma..N Engl J Med2015;373:23-34 PMCID:PMC5698905

[39] Voron T,Marcheteau E,Nizard M.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors..J Exp Med2015;212:139-48 PMCID:PMC4322048

[40] Limagne E,Thibaudin M,Derangère V.Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen..Cancer Res2016;76:5241-52

[41] Triplett TA,Triplett KC,Sun L.STAT3 signaling is required for optimal regression of large established tumors in mice treated with anti-OX40 and TGFβ receptor blockade..Cancer Immunol Res.2015;3:526-35

[42] Schaer D,Castaneda S,Surguladze D.Targeting the TGF pathway with galunisertib, a TGF-RI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition..J Immunother Cancer2015;3:P402 PMCID:PMC4652527

[43] Watson NF,Madjd Z,Ellis IO.Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis..Int J Cancer2006;118:6-10

[44] Lal N,Goussous G,Mason MJ.KRAS mutation and consensus molecular subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer..Clin Cancer Res2018;24:224-33 PMCID:PMC5777581

[45] Ebert PJR,Yang Y,Hong R.MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade..Immunity2016;44:609-21

[46] Bendell JC,Chee CE,McRee AJ.A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC)..J Clin Oncol2018;

[47] Chen N,Zhan J,Tang Y.Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation..J Thorac Oncol2015;10:910-23

[48] Klein C,Nicolini VG,Nayak T.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines..Oncoimmunology2017;6:e1277306 PMCID:PMC5384349

[49] Tabernero J,Ros W,Marabelle A.Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC)..J Clin Oncol2017;

[50] Segal NH,Cercek A,Raasch PJ.Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients..J Clin Oncol2016;

[51] Shahda S,Bekaii-Saab TS,Sehdev A.A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer..J Clin Oncol2017;

[52] Orillion A,Damayanti N,Adelaiye-Ogala R.Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma..Clin Cancer Res2017;23:5187-201 PMCID:PMC5723438

[53] Azad NS,McRee AJ,Johnson DB.ENCORE 601: a phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer..J Clin Oncol2018;

[54] Magee MS,Baybutt TR,Ridge NA.Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases..Cancer Immunol Res2018;6:509-16

[55] Huang Q,Wang L,Ma X.miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy..J Hematol Oncol2018;11:58 PMCID:PMC5914051

[56] Fabrizio DA,Dunne RF,Sun J.Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition..J Gastrointest Oncol2018;9:610-7 PMCID:PMC6087857